Perspectives on the Treatment of Malignant Pleural Mesothelioma
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Most mesotheliomas originate in the pleura and are due to asbestos exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality remains high in part because of late diagnosis and treatment resistance. Pemetrexed–cisplatin and immune checkpoint inhibitors modestly extend survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Deep learning-based classification of mesothelioma improves prediction of patient outcome
Courtiol, P., Maussion, C., Moarii, M., Pronier, E., Pilcer, S., Sefta, M., Manceron, P., Toldo, S., Zaslavskiy, M., Le Stang, N., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0583-3 · Cited by 544
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30765-4 · Cited by 454
Popat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., Roy, A., Gilligan, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.009 · Cited by 271
Ceresoli, G. L., Aerts, J. G., Dziadziuszko, R., Ramlau, R., Cedres, S., van Meerbeeck, J. P., Mencoboni, M., Planchard, D., Chella, A., Crinò, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30532-7 · Cited by 164
Cited by
Activation of Tumor-Cell STING Primes NK-Cell Therapy
Knelson, E. H., Ivanova, E. V., Tarannum, M., Campisi, M., Lizotte, P. H., Booker, M. A., Ozgenc, I., Noureddine, M., Meisenheimer, B., Chen, M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0017 · Cited by 88
Metadata
- Authors
- Janes, S. M., Alrifai, D., & Fennell, D. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1207-1218
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3201306276
- Cited by
- 186
- References
- 13
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perspectives on the Treatment of Malignant Pleural Mesothelioma. https://app.cochat.ai/papers/10.1056/nejmra1912719
- The paper
- Janes, S. M., Alrifai, D., & Fennell, D. A. (2021). Perspectives on the Treatment of Malignant Pleural Mesothelioma. New England Journal of Medicine. https://doi.org/10.1056/nejmra1912719
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.